Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                Guidance, Compliance, & Regulatory Information

Guidance, Compliance, & Regulatory Information

                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities Home
          Drugs
          Guidance, Compliance, & Regulatory Information
          “Deemed to be a License” Provision of the BPCI ActGuidance, Compliance, & Regulatory Information “Deemed to be a License” Provision of the BPCI Act
  
  	
    Share
    Post
    Linkedin

    Email
    PrintThe Biologics Price Competition and Innovation Act of 2009 (BPCI Act) requires that a marketing application for a “biological product” (that previously could have been submitted under section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act)) must be submitted as a biologics license application (BLA) under section 351 of the Public Health Service Act (PHS Act). This requirement is subject to certain exceptions during a 10-year transition period ending on March 23, 2020.

On March 23, 2020, the BPCI Act requires that an approved marketing application for a “biological product” under section 505 of the FD&C Act shall be deemed to be a license for the biological product (i.e., an approved BLA) under section 351 of the PHS Act. The 10-year transition period between the law’s enactment on March 23, 2010, and March 23, 2020, provides sponsors of biological products that are affected by the statutory transition with time to prepare for the transition, and allows biological products submitted under section 505 of the FD&C Act time to be approved before March 23, 2020.

FDA is working to ensure that there is a seamless transition between regulatory pathways and that there are minimal impacts on manufacturers and patients.

Background:

Although the majority of therapeutic biological products have been licensed under the PHS Act, some protein products (e.g., insulin and insulin analogs, human growth hormone, pancreatic enzymes, reproductive hormones) historically have been approved in new drug applications (NDAs) under the FD&C Act.

The BPCI Act clarified the statutory authority under which these protein products will be regulated by amending the statutory definition of a “biological product” in the PHS Act to include a “protein (except any chemically synthesized polypeptide),” and describing procedures for submission of a marketing application for these protein products. The Further Consolidated Appropriations Act, 2020, enacted on December 20, 2019, further amended the definition of a “biological product” in the PHS Act to remove the parenthetical “(except any chemically synthesized polypeptide)” from the statutory category of “protein,” meaning that such chemically synthesized products are now within the definition of “biological product” and subject to the statutory transition. This legislative change only affects chemically synthesized products that fall within the interpretation of “protein” (see updated Preliminary List below); this legislative change does not affect “peptides” (i.e., polymers composed of 40 or fewer amino acids).

For proposed products, the BPCI Act describes the approval pathways that are available for submission of a marketing application for biological products subject to the transition. After March 23, 2020, all sponsors seeking approval of a biological product that previously could have been submitted under section 505 of the FD&C Act will need to submit a marketing application under section 351 of the PHS Act; either:

	a 351(a) BLA (i.e., a “stand-alone” BLA); or
		a 351(k) BLA for a proposed biosimilar product or a proposed interchangeable product.
	For approved products, the BPCI Act requires that an approved marketing application for a “biological product” under section 505 of the FD&C Act be deemed to be a license for the biological product (i.e., an approved BLA) under section 351 of the PHS Act on March 23, 2020, and regulated under the PHS Act. Once this transition occurs, sponsors can seek approval of products that are biosimilar to, or interchangeable with, these transitioned products.For additional information on the statutory transition, please refer to the resources below.

Resources:

FDA Guidance for Industry, Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009
	FR Notice
		Final Guidance
	FDA Guidance for Industry, The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers
	FR Notice
		Final Guidance
	Definition of the Term “Biological Product”, Final Rule
	MAPP 5016.3 - Responsibility in OPQ for the Integrated Quality Assessment of Products Containing Drug Substances Composed of Amino Acid Polymers
	List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 (corrected)
	List of Withdrawn Applications for Biological Products That Were Removed From FDA’s Orange Book on March 23, 2020
	Other Information and Resources
	Information for Patients About Regulatory Changes for Certain Biological Product Medications
		Information for Health Care Providers About Regulatory Changes for Certain Biological Product Medications
		FDA Biosimilars Website
		The Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations
		Archived copy of the Orange Book on March 20, 2020 (PDF - 10 MB)
	Biologics License Applications and Master Files, A Proposed Rule by the Food and Drug Administration on 06/28/2019
	Changes that affect compounding as of March 23, 2020

                                                                                  Content current as of:
      04/02/2020Guidance, Compliance, & Regulatory Information

          
                        Good Review Practices | GRPs


                        Guidances | Drugs
          Electronic Drug Registration and Listing System (eDRLS)
          CDER FOIA Electronic Reading Room
          CDER International Program
          Enforcement Activities | FDA
          Human Drug Compounding
          Human Drug Exports
          Human Drug Imports
          Laws, Acts, and Rules
          Postmarketing Requirements and Commitments: Introduction
          Surveillance: Post Drug-Approval Activities
 
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop